» Articles » PMID: 19689738

The Relationship Between Human Effector and Memory T Cells Measured by Ex Vivo and Cultured ELISPOT Following Recent and Distal Priming

Overview
Journal Immunology
Date 2009 Aug 20
PMID 19689738
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Maintenance of T-cell responses is an essential feature in protection from many infectious diseases that must be harnessed in vaccination. The relationship between effector T-cell responses and more durable and highly proliferative T-cell memory, particularly in humans, is not well understood. In this study, effector T-cell responses were measured by overnight ex vivo interferon-gamma (IFN-gamma) enzyme-linked immunosorbent spot-forming cell assay (ELISPOT), whereas memory T cells were measured by 10-day culture followed by IFN-gamma ELISPOT (cultured ELISPOT). We observed a significant correlation between IFN-gamma responses to CD4-stimulatory, but not to CD8-stimulatory, recall antigens measured by these assays, suggesting a divergence in regulation. In vaccine trial participants who received a prime-boost vaccination regimen comprising malaria antigens delivered by poxviruses, there was a correlation between ex vivo and cultured responses on day 7, but not 3 months post-vaccination, with the ratio of cultured : ex vivo response increasing over time. To compare responses revealed by cultured ELISPOT in more detail, tetramers comprising viral recall antigens were used to ascribe effector-memory and central-memory T-cell phenotypes through CCR7 and CD62L costaining. For CD8(+) responses the effector phenotype decreased during the initial culture period and memory populations remained high within the resulting 20-fold to 50-fold increased IFN-gamma-secreting or tetramer(+) population. This was less marked for CD4(+) responses, which had higher starting memory phenotype. Depletion of these central-memory T-cell populations generally ablated responses in cultured ELISPOT and reduced ex vivo responses. This study highlights differences between CD4(+) and CD8(+) effector and memory T cells, and the more complex phenotype of CD4(+) T cells.

Citing Articles

Maximizing Insights, Minimizing Animal Testing: A Framework for Validating Multiparametric Single-Cell Cytokine Analysis Panels.

Aleith J, Bergmann-Ewert W, Muller-Hilke B Eur J Immunol. 2025; 55(3):e202451193.

PMID: 40071676 PMC: 11898573. DOI: 10.1002/eji.202451193.


Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer.

Talpin A, Maia A, Carpier J, Kulakowski G, Aubergeon L, Kervevan J J Immunother Cancer. 2025; 13(2).

PMID: 39979071 PMC: 11842988. DOI: 10.1136/jitc-2024-010192.


Frequent detection of IFN-gamma -producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy.

de Goer de Herve M, Dekeyser M, Hendel-Chavez H, Maillart E, Labeyrie C, Adams D Front Immunol. 2024; 15:1416074.

PMID: 39086476 PMC: 11289500. DOI: 10.3389/fimmu.2024.1416074.


Predominantly defective CD8 T cell immunity to SARS-CoV-2 mRNA vaccination in lung transplant recipients.

Taus E, Shino M, Ibarrondo F, Hausner M, Hofmann C, Yang O J Transl Med. 2023; 21(1):374.

PMID: 37291575 PMC: 10248978. DOI: 10.1186/s12967-023-04234-z.


Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.

Taus E, Hofmann C, Ibarrondo F, Gong L, Hausner M, Fulcher J Front Immunol. 2023; 14:1100594.

PMID: 36860850 PMC: 9968837. DOI: 10.3389/fimmu.2023.1100594.


References
1.
Lucas M, Day C, Wyer J, Cunliffe S, Loughry A, McMichael A . Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells. J Virol. 2004; 78(13):7284-7. PMC: 421690. DOI: 10.1128/JVI.78.13.7284-7287.2004. View

2.
Todryk S, Bejon P, Mwangi T, Plebanski M, Urban B, Marsh K . Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS One. 2008; 3(4):e2027. PMC: 2323567. DOI: 10.1371/journal.pone.0002027. View

3.
Yang S, Lee C, Park S, Im S, Kim Y, Son J . Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther. 2006; 13(14):1110-7. DOI: 10.1038/sj.gt.3302751. View

4.
Harari A, Vallelian F, Meylan P, Pantaleo G . Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol. 2005; 174(2):1037-45. DOI: 10.4049/jimmunol.174.2.1037. View

5.
Currier J, Kuta E, Turk E, Earhart L, Loomis-Price L, Janetzki S . A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods. 2002; 260(1-2):157-72. DOI: 10.1016/s0022-1759(01)00535-x. View